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troversial for some authors. Three meta-analyses of the literature,
from three different groups, concluded that the survival effect of
corticosteroids was restricted to patients with severe disease.
Conversely, two other meta-analyses of the literature from the
same group questioned the efﬁcacy of corticosteroids in alcoholic
hepatitis, regardless of disease severity, although their latest
meta-analysis observed that corticosteroids reduced mortality
signiﬁcantly in the subgroup of trials in patients with Maddrey
discriminant functionP32 or hepatic encephalopathy [1]. Unex-
pectedly, their latest meta-analysis included some inaccuracies:
(i) the authors considered Richardet’s study to be a trial compar-
ing corticosteroids with no treatment, whereas both arms were
treated with corticosteroids (information provided by Dr. Richar-
det); (ii) mortality data in the short-term were mixed with long-
term mortality data; and (iii) the authors included a study (Gal-
ambos) quoted by another author (Conn) that has never been
published even in abstract form.
In fact, the main limit of meta-analysis of the literature in
alcoholic hepatitis is that evaluation of any treatment effect on
short-term survival is achievable only in the subgroup of patients
with a signiﬁcant risk of death in the short-term. For that pur-
pose, the use of reproducible tools is mandatory but this require-
ment was not met in most studies published before the Maddrey
discriminant function (DF) became available. In numerous stud-
ies from different groups aiming to predict short-term mortality,
the AUROC curve of DF is around 0.8 in patients with severe and
non-severe forms [2,3]. The prognostic values of DF was con-
ﬁrmed by several independent groups showing that spontaneous
short-term survival of patients with a DF P32 ﬂuctuated
between 50% and 65% [2–5] whereas 28-day survival of patients
with a DF <32 is close to 90% [6].
It is not a reasonable approach to evaluate treatment impact
in patients with a negligible risk of death during exposure to
the drug. However, meta-analysis of the literature cannot pool
the results restricted to patients with DFP32 as most of the pre-
vious RCTs did not supply the speciﬁc survival data of this sub-
group. Christensen and his colleagues stated that the variability
of severity is not an issue as, in their meta-analysis, most of theJournal of Hepatology 20
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curate statement is related to the fact that they combined long-
term survival data from some studies with short-term survival
in others. How can clinicians consider long-term survival data
as a relevant endpoint to analyze the impact of just 28 days of
exposure to any compound in an acute process? How can a com-
parison be performed using different mortality endpoints? As an
example, the exact data on short-term mortality for the cortico-
steroid group is 15/90 instead of 55/90 in the Mendenhall study
[6] and 1/24 instead of 5/24 in Bories’ study [7]. The prognostic
value of DF is conﬁrmed by the fact that, in Mendenhall’s study,
approximately 85% of deaths were observed in the subgroup of
patients with DF P32. Thus, therapeutic intervention for short-
term outcome must focus only on patients with DF P32.
The use of meta-analyses combining individual data is war-
ranted in order to overcome the limitations associated with using
the literature for comparative purposes. The need for such an
approach is conﬁrmed by the fact that, 20-year truth survival of
conclusions derived from meta-analysis from the literature was
lower (57%) than that from non-randomized studies (87%)
(p <0.001) or randomized trials (85%) [8]. Whenever possible, a
meta-analysis of individual patient data should be done because
this provides the least biased and most reliable means of address-
ing questions that have not been resolved satisfactorily by indi-
vidual clinical trials. In the speciﬁc setting of the evaluation of
corticosteroids in patients with severe alcoholic hepatitis only a
meta-analysis combining individual data is able to obtain
detailed information from each individual with DFP32 or hepa-
tic encephalopathy.
Therapeutic intervention which improves liver function is lia-
ble to improve short-term survival and studies focusing on a
strategy integrating the early impact of treatment on liver func-
tion are warranted [9]. Early improvement in liver function is
very useful clinically in predicting short-term survival of patients
with severe alcoholic hepatitis whether or not they are treated
with corticosteroids [3,10]. A recent international study com-
bined individual data of patients with DFP32 or encephalopathy
from the ﬁve most recent randomized controlled trials comparing
corticosteroids to placebo or any inefﬁcient treatment [11].
Approximately 400 patients were included. The 28-day survival
was signiﬁcantly higher in corticosteroid treated than in non-cor-
ticosteroid treated patients (79% vs 64%, p = 0.0005). Corticoste-
roid treated patients had an early and greater improvement of
liver function and a better response to the assigned therapy
assessed by the Lille model, a score integrating early improve-10 vol. 53 j 392–393
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ment in its formula. In a multivariate analysis, DF, and the Lille
model, encephalopathy and corticosteroid treatment were associ-
ated independently with short-term survival [11]. This study
should end the controversy surrounding the short-term efﬁcacy
of corticosteroids in severe alcoholic hepatitis.
However, the current therapy for alcoholic hepatitis (i.e. corti-
costeroids and/or pentoxifylline) is not effective in all patients.
Early identiﬁcation of responders with a substantial improve-
ment in hepatic function following treatment with corticoste-
roids constitutes an advance in the management of severe
alcoholic hepatitis [10]. Conversely, in non-responders without
an early improvement in hepatic function, novel therapies are
needed urgently.
For all of these reasons, the recent American practice guide-
lines recommend the use of corticosteroids or pentoxifylline for
patients with severe alcoholic hepatitis as deﬁned by the Mad-
drey DF [12].
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